Introduction
Although D-penicillamine (3.3-dimethyl cystine) has had a long career as a therapeutic agent in a varied and increasing number of diseases, because of its unusual introduction into the clinical field relatively little information is available on its metabolism in man. More is known about its absorption and metabolism in the rat following the work of Wass & Evered (1970) on intestinal absorption, and the work of Planas-Bohne (1972) and Ruis-Torres (1974a , 1974b and Ruis-Torres & Kurten (1974) using 14C-labelled D-penicillamine.
In 1971 Gibbs & Walshe published the results of a study, using 35S-labelled penicillamine, in 6 patients with Wilson's disease. Unfortunately the material employed was the racemic mixture and because the D-and L-isomers of penicillamine behave in substantially different ways biochemically, their findings are of limited value. D-penicillamine is an amino acid with one thiol group and occurs naturally as part of the penicillin molecule. The metabolism of D-penicillamine in man is closely linked to the chemical properties of that active thiol group. Those properties are metal chelation, disulphide formation with other thiol-containing amino acids, whether free or in protein structures, and thiazolidine formation. The first property is the one of value in treating Wilson's disease and heavy metal poisoning and the second provides the rationale for the treatment of cystinuria. Before the present studies the only identified metabolites of penicillamine were the internal disulphide and the mixed disulphide with cysteine (Crawhall et al. 1963 ).
This paper outlines the investigations into the metabolism of D-penicillamine at St Bartholomew's Hospital where, since its introduction into the treatment of cystinuria by Crawhall et al. (1963) , some 30 patients have been treated for long periods with D-penicillamine (see Stephens p 24).
Materials and Methods D-penicillamine used in these studies was either the free base or the hydrochloride (Distamine). D-(2-14C)-penicillamine hydrochloride was obtained from the Radiochemical Centre, Amersham (this is not in the catalogue and only a small quantity is available). It was prepared from DL-(2-14C) valine and the isomers were resolved via the brucine salt of the N-formylisopropylidene derivatives. The product was 97-98 % pure, with a specific activity of 3 mCi/mmol. Radioactivity was measured using a Nuclear Chicago Mark I liquid scintillation counter. Samples were counted in a gelling scintillation mixture (Unisolve Koch-Light, Colnbrook). All quantitative measurements of metabolites were performed on a-single column amino acid analyser employing gradient elution. The subjects studied had been receiving D-penicillamine for at least one month before the urine collection and/or balance studies. All urines were acidified on collection to prevent further disulphide exchange.
Metabolic Studies
The urinary amino acid chromatograms from cystinuric subjects receiving D-penicillamine show a reduction in the cystine peak from the large pretreatment peak and the formation of cysteinepenicillamine mixed disulphide and penicillamine disulphide. A section of a typical chromatogram is shown in Fig 1 Recently we have identified a further metabolite shown on the chromatogram as S-methyl Dpenicillamine. This metabolite was isolated from urine by ion-exchange chromatography and high voltage electrophoresis, its structure was then determined by mass spectrometry and confirmed by synthesis (Perrett et al. 1976) . The results of a quantitative study of these three urinary metabolites are summarized in Table 1 .
In the cystinuric subjects the dosage of Dpenicillamine ranged from 1 to 3 g per day and the metabolite pattern was found to be independent of dose. Less than half the penicillamine dose was found in the urine as identified metabolites. The major metabolite was cysteinepenicillamine disulphide, which accounted for about one quarter of the dose. The slightly lower percentage of the dose excreted in urine by the Wilson's disease and rheumatoid arthritis (RA) patients was mainly due to the reduced excretion of the mixed disulphide. In no case did S-methyl-D-penicillamine account for more than 10% of the dose.
Although D-penicillamine caused an increase in the urinary excretion of total cysteine (excreted as cystine and cysteine-penicillamine disulphide) in Wilson's disease and RA. Methylation of Dpenicillamine by S-adenosylmethionine probably accounted for the 30 % reduction in 'total cysteine' excretion found in cystinuric patients receiving D-penicillamine (Crawhall & Thompson 1965 , Perrett et al. 1976 ). Penicillamine therefore significantly affects cysteine synthesis as well as cystine excretion in cystinuria.
Because the urinary metabolites of D-penicillamine accounted for less than half the dose of the drug, a balance study was performed on 4 cystinuric subjects who were receiving a regular constant dose of the drug. Urinary and fvcal metabolites were measured by chromatography over a period ranging from five to seven days, and the results are summarized in Table 2. The only significant fecal metabolite that could be identified was the internal disulphide, and less than 16% of the dose could be found in the fices. The overall recovery in urine plus feces averaged 47 % in the 4 subjects. Therefore in a typical cystinuric or Wilson's disease subject, up to 0.5 kg of D-penicillamine was unaccounted for each year. Because of this high 'loss', the need to receive treatment for a lifetime, and the possible serious side-effects, a better understanding of this loss seemed desirable.
It was probable that D-penicillamine, being a D-amino acid and presumably without specific carrier mechanisms in the gut, was not being absorbed but suffered bacterial degradation to unknown metabolites. At that time we were investigating the intestinal absorption of peptides and amino acids in our cystinuric patients, using an intestinal perfusion technique (Silk et al. 1974 ). The solutions under study are perfused at known concentrations through 30 cm sections of the small intestine using a double-lumen perfusion tube incorporating a proximal occlusive ) were found f a 2 mmol/1 solution in bo subjects. On the othe: disulphide was negligibl with a passive diffusion views are that D-penicill containing compounds t the gut before absorptioi aids absorption. Work to hypothesis is in progress full elsewhere (Perrett, preparation) . So, although D-penicil well absorbed by the gut i) of dose found in the ba more puzzling. The recen quantity of labelled D-pe a single preliminary n performed in a normal ma The subject received 15 hydrochloride twice a de seventh day a solution o water was taken at 10. 250 mg tablet of D-penici 3 x 106 cpm was given. Ee fices specimen was then collected for the next three days. 14C radioactivity was measured, using URINE internal standardization, corrected to constant efficiency, and the percentage of the dose calculated. Fig 2 shows the accumulated excretion figures for urine and fieces.
-The 14C-D-penicillamine was rapidly excreted in the urine. Half the dose was found in the urine in 48 h, and in the first eight hours. Fmecal excre-,' /tion accounted for some 35% over a three-day / FAECES period. // On the fourth day liltle 14C was present in the faeces. It is reasonable to assume that deficit of 15% in this preliminary study resulted from counting errors in the feces where colour quenching of the counts was significant, particularly as previous animal studies have indicated little breakdown to 14CO2 (Planas-Bohne 1972) . Improved counting procedures should eliminate this error in a fuller study. Because previously ( At the 1"C dose used, accurate measurements it of the concentration of plasma and red-cell radioactivity were not collected by siphonage, possible, but the crude measurements made can be quantitated. confirm the findings of Gibbs & Walshe (1971) of absorption, comparable significant binding of D-penicillamine to serum nd for L-cysteine (Silk proteins. or 
D-penicillamine from
Because of the long-term effects of D-penicilth normal and cystinuric lamine in man, further work using the 14Cr hand, penicillamine labelled compound is desirable, but because of ly absorbed, consistent the long biological half-life the studies must be process. Our present performed with the utmost care. amine and other thiol-It is possible that differences in the pattern of )ind to the proteins of metabolism may correlate with the types of siden, and this significantly effects observed during treatment with Dextend and confirm this penicillamine. and will be published in Fairclough & Silk, in llamine was apparently n vivo, the deficit of 50 % tlance studies was even It availability of a small nicillamine has enabled ietabolic study to be tle. i0 mg of D-penicillamine ay for 10 days. On the ,f 14C-D-penicillamine in 30 a.m. along with a illamine base. A dose of ich individual urine and Summary in a study using 14C-D-penicillamine in a normal subject only 50% of the D-penicillamine was absorbed from the gut. The major urinary metabolites are cysteine-penicillamine and penicillamine disulphide. S-methyl-D-penicillamine is the only biochemically transformed metabolite so far identified.
